Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 260-265

  Lukason, Michael ^a   Dufresne, Elizabeth ^a   Rubin, Hillard ^a   Pechan, Peter ^a   Li, Qiuhong ^b   Kim, Ivana ^c   Kiss, Szilard ^c   Flaxel, Christina ^d   Collins, Margaret ^e   Miller, Joan ^c   Hauswirth, William ^b   MacLachlan, Timothy ^a   Wadsworth, Samuel ^a   Scaria, Abraham ^a  

^a GENZYME CORPORATION   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

MURINAE; PRIMATES;

EID: 79551652669     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.230     Document Type: Article

References (20)

1. Adamis, AP, Miller, JW, Bernal, MT, D'Amico, DJ, Folkman, J, Yeo, TK et al. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450.
2. Kvanta, A, Algvere, PV, Berglin, L and Seregard, S (1996). Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934.
3. Aiello, LP, Pierce, EA, Foley, ED, Takagi, H, Chen, H, Riddle, L et al. (1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461.
4. Brown, DM, Kaiser, PK, Michels, M, Soubrane, G, Heier, JS, Kim, RY et al.; ANCHOR Study Group. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
5. Rosenfeld, PJ, Brown, DM, Heier, JS, Boyer, DS, Kaiser, PK, Chung, CY et al.; MARINA Study Group. (2006). Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
6. D'Amico, DJ, Masonson, HN, Patel, M, Adamis, AP, Cunningham, ET Jr, Guyer, DR et al.; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. (2006). Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113: 992-1001.e6.
7. Kay, MA, Manno, CS, Ragni, MV, Larson, PJ, Couto, LB, McClelland, A et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261.
8. Marks, WJ Jr, Ostrem, JL, Verhagen, L, Starr, PA, Larson, PS, Bakay, RA et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7: 400-408.
9. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105.
10. Mueller, C and Flotte, TR (2008). Clinical gene therapy using recombinant adenoassociated virus vectors. Gene Ther 15: 858-863.
11. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
12. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
13. Cideciyan, AV, Hauswirth, WW, Aleman, TS, Kaushal, S, Schwartz, SB, Boye, SL et al. (2009). Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20: 999-1004.
14. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
15. Bainbridge, JW, Mistry, A, De Alwis, M, Paleolog, E, Baker, A, Thrasher, AJ et al. (2002). Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 9: 320-326.
16. Lai, CM, Shen, WY, Brankov, M, Lai, YK, Barnett, NL, Lee, SY et al. (2005). Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12: 659-668.
17. Pechan, P, Rubin, H, Lukason, M, Ardinger, J, DuFresne, E, Hauswirth, WW et al. (2009). Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16: 10-16.
18. Lebherz, C, Maguire, AM, Auricchio, A, Tang, W, Aleman, TS, Wei, Z et al. (2005). Nonhuman primate models for diabetic ocular neovascularization using AAV2- mediated overexpression of vascular endothelial growth factor. Diabetes 54: 1141-1149.
19. Dalkara, D, Kolstad, KD, Caporale, N, Visel, M, Klimczak, RR, Schaffer, DV et al. (2009). Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 17: 2096-2102.
20. Acland, GM, Aguirre, GD, Ray, J, Zhang, Q, Aleman, TS, Cideciyan, AV et al. (2001). Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28: 92-95.